MedPath

Evaluation of mucosal healing effects of intensive-granulocyte monocyte absorptive apheresis in patients with ulcerative colitis

Not Applicable
Recruiting
Conditions
lcerative colitis
Registration Number
JPRN-UMIN000039958
Lead Sponsor
ational Defense Medical College
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1.Patients with granulocyte count 2,000/mm3 or less 2.Patients with serious infectious disease 3.Patients with proctitis 4.Patients who used of enema, suppository (mesalazine, sulfasalazine, steroids) within the last 2 weeks 5.Patients who started administration or increased the dosage of mesalazine, sulfasalazine within the last 4 weeks 6.Patients who started administration or increased the dosage of steroids (oral) within the last 2 weeks 7.Patients who received steroids (intravenous infusion) within the last 2 weeks 8.Patients who used of total parenteral nutrition within the last 4 weeks 9.Patients who received cyclosporine, tacrolimus within the last 4 weeks 10.Patients who started administration or increased the dosage of azathioprine, 6-mercaptopurine within the last 4 weeks 11.Patients who received infliximab within the last 6 weeks 12.Patients who used of GMA, LCAP within the last 8 weeks 13.Patients with history of colectomy 14.Patients with inappropriate for this study by doctor's judgement 15.Patients who refused to participate in this study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Mucosal healing rate (Endoscopic score of Mayo index)
Secondary Outcome Measures
NameTimeMethod
Remission rate (Mayo score) Efficacy (Mayo score) Changes in mRNA expression levels of inflammation associated molecules in colonic mucosa
© Copyright 2025. All Rights Reserved by MedPath